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Background: GAD65 (Glutamic acid decarboxylase 65 KDa isoform) is one of the most important auto-antigens
involved in Type 1 diabetes induction. Although it serves as one of the first injury markers of β-islets, the
mechanisms governing GAD65 expression remain poorly understood. Since the regulation of GAD65 is crucial for
the proper functioning of insulin secreting cells, we investigated the stress induced regulation of GAD65
transcription.
Results: The present study shows that SMAR1 regulates GAD65 expression at the transcription level. Using a novel
protein-DNA pull-down assay, we show that SMAR1 binding is very specific to GAD65 promoter but not to the
other isoform, GAD67. We show that Streptozotocin (STZ) mediated DNA damage leads to upregulation of SMAR1
and p53 expression, resulting in elevated levels of GAD65, in both cell lines as well as mouse β-islets. SMAR1 and
p53 act synergistically to up-regulate GAD65 expression upon STZ treatment.
Conclusion: We propose a novel mechanism of GAD65 regulation by synergistic activities of SMAR1 and p53.
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Type1 diabetes is an immunologically encountered
autoimmune disease characterized by specific destruc-
tion of beta cells of islets of langerhans residing in pan-
creas [1]. This specific response to beta cells is caused
due to immune response against self molecules that be-
have as non-self (known as auto antigens). GAD (Glu-
tamic acid decarboxylase) which is involved in synthesis
of Gamma-Amino butyric acid or GABA, a neurotrans-
mitter inhibitor [2,3], is considered to be one of the
strongest candidate auto antigens involved in triggering
beta-cell-specific autoimmunity [4]. Majority of recent
type 1 diabetes patients and pre-diabetic subjects have
anti-GAD antibodies in their sera, as do non-obese dia-
betic (NOD) mice, one of the best animal models for
human type I diabetes. Immunization of young NOD
mice with GAD results in prevention or delay of the
disease as a result of tolerizing auto reactive T cells [4].* Correspondence: sandeepsingh82@gmail.com; samit@nccs.res.in
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reproduction in any medium, provided the orOn the other hand over-expression of GAD65 transgene
in animal tissues can exacerbate the disease instead of
tolerizing the animal [4]. GAD usually occurs in two
major isoforms; GAD65 and GAD67, encoded by two
non-allelic genes located on different chromosomes [5]
and are differentially regulated in various mammalian
species. In beta cells of human and rat GAD65 is pre-
dominant, while in mouse though both the forms occur
GAD67 predominates over GAD65 [6-8]. Although the
expression level of GAD65 is extremely low in mouse
β-islets, it is one of the major islet auto antigens [7-9].
Despite studies on the role of GAD65 in diabetes in-
duction using various in-vitro and in-vivo models of
spontaneous autoimmune diabetes [10,11], the initial
islet-specific factor(s) and the molecular mechanisms
triggering the aberrant expression of GAD65 is still not
very clear. The smaller form of the GAD auto-antigen
namely GAD65, is a major target of humoral auto-
immunity in type-1 diabetes. Recent data suggest that
GAD65 expression in beta cells varies according to the
functional state and the kind of stress [12]. High glu-
cose and glutamine have been shown to be putative
positive regulators of GAD65 expression [13-15], whiletd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Singh et al. BMC Molecular Biology 2012, 13:28 Page 2 of 12
http://www.biomedcentral.com/1471-2199/13/28cytokines like IL-1 beta have been shown to act as
negative regulators [15]. GAD is an enzyme found in
high concentration in the pancreas and brain where it
catalyzes the conversion of glutamic acid to gamma-
amino butyric acid (GABA). GABA is an inhibitory
neurotransmitter that is important in the pancreas as a
messenger between neurons and pancreatic cells
[16,17]. Specific experiments in animal models have
shown that GAD expression is necessary for the auto-
immune destruction of cells. One study in particular,
performed on NOD mice (which are close to humans
in their autoimmune manifestation of IDDM), incorpo-
rated an antisense GAD transgene into a subset of mice
and found that IDDM development was significantly
reduced [18].
Streptozotocin (STZ), derived from a fermentation
broth of Streptomyces achromogenes, has been widely
used to study the beta cell destruction both in-vitro and
in-vivo models [19,20]. The drug Streptozotocin (STZ) is
a glucose analogue (N-[methylnitrosocarbamoyl]-D-glu-
cosamine) that is rapidly transported into the β-cells via
the glucose transporter, Glut2 [21] and is known to be
metabolized readily upon entry into the cell. The exact
mechanism of STZ’s toxicity is not fully understood, but
it has been suggested that its primary effect on beta cells
is DNA damage by alkylation, unscheduled DNA synthe-
sis, DNA adducts, chromosomal aberrations and DNA
strand breaks induced by free radical generation [22,23].
The tumor suppressor protein p53 can cause cell cycle
arrest upon DNA damage induced activation [24-30]. In
doing so, it facilitates the repair of damaged DNA or
eliminates irreversibly damaged or abnormally growing
cells to prevent potential transformation. Mdm2 helps to
maintain steady state levels of p53 under normal condi-
tion through ubiquitination pathway [31-33]. STZ has
also been shown to induce p53 protein in MIN6 cells
[34] but the exact mechanism is largely unknown. One
study also reported p53 antibodies circulating in patients
suffering from type-1 diabetes [35].
Gene regulation is one of the most complex processes
involving cross talk between a variety of proteins, nu-
clear matrix, DNA and many other DNA binding fac-
tors. The function of nuclear matrix is to provide a solid
platform for efficient transcription. A number of matrix
associated DNA region binding proteins (MARBPs) are
known to be involved in regulation of transcription.
SMAR1 is one such MARBP which was earlier shown to
be involved in the regulation of Cyclin D1 and CK8 ex-
pression [36,37]. SMAR1 specifically binds to putative
MAR (MARβ) of the transcriptional enhancer (Eβ) at
the T-cell receptor-β locus [38,39]. This protein is
known to cause cell cycle arrest and activates p53
through its serine 15 phosphorylation as well as through
disruption of its interaction with MDM2 [40-43]. It is apotent tumor suppressor protein and significantly down-
regulated in higher grades of breast cancer [44].
The present study delineates a novel mechanism of
regulation of GAD65 expression by two tumor suppressor
proteins, SMAR1 and p53. We show that both the pro-
teins can individually and synergistically upregulate
GAD65 expression. We demonstrate that SMAR1 binds
to GAD65 promoter in vitro and in-vivo to upregulate its
mRNA expression. Our results show that STZ treatment
leads to upregulation of SMAR1 and p53 expression. On
the other hand MDM2 expression is downregulated lead-
ing to increased stability of p53. The stabilized p53 in turn
binds to SMAR1 leading to an increased expression of
GAD65. We also show a temporal increase of SMAR1 and
p53 proteins on GAD65 promoter upon STZ treatment.
Further studies using mouse β-islets confirmed our find-
ings regarding the synergy between p53 and SMAR1 in
GAD65 expression. Taken together, our results reveal a
novel mechanism of regulation of major auto antigen
GAD65 by SMAR1 and p53.
Results
SMAR1 binds to multiple DNA sequences in genome
SMAR1 is documented to be a transcriptional activator/
repressor in a context dependent manner, based on its
DNA binding abilities. In vivo, SMAR1 binds to the pro-
moters of Cyclin D1 and 5' UTR of cytokeratin 8
[36,37]. To gain a better understanding of the transcrip-
tion regulatory activities of SMAR1, we wanted to delin-
eate various genomic DNA sequences bound by
SMAR1. Therefore, we resorted to a novel pull down
assay. Briefly, mouse genomic DNA was sheared to ob-
tain small fragments of approximately 500 bp. These
fragments were incubated with glutathione bead bound
GST-SMAR1 recombinant protein and the bound DNA
fragments were subsequently sequenced. Glutathione
beads as well as bead bound GST were the controls used
to negate non- specific binders. The resulting fragments
were sequenced and then aligned using MEME software
and a 50 mer consensus was derived (Figure 1A). Fur-
ther manual alignments of the derived sequences lead to
identification of a hexamer (TAATPu/Py Pu) consensus
SMAR1 binding sequences where first four nucleotides
are conserved while fifth one can be either pyrimidine
or purine and the last nucleotide is either of the purines
(Figure 1A, sequence shown in red). Further, we were
able to validate our method by identification of some of
the already known promoters bound by SMAR1, includ-
ing cyclin D1 [36], Bax [45], 5' UTR of cytokeratin 8
[37]. One of the unique promoters found to be bound
by SMAR1 was GAD65 while the other isoform of GAD
i.e. GAD67 promoter did not show any binding. In order
to confirm that SMAR1 indeed binds to the GAD65 pro-
moter, we performed CNBr pull down assay. The
Figure 1 Isolation of DNA fragments bound by SMAR1. A. MEME software based alignment of the SMAR1 binding DNA sequences for the
consensus for SMAR1 binding. B. CNBr pull down assay (by consensus and by GAD65 promoter DNA) samples were processed for western blot
analysis using SMAR1 specific antibody. PI represents pre-immune and Imm represents the immune complexes. C & D. GST-p53, GST-SMAR1,
GST-Rxn5 (DNA binding domain of SMAR1), GST-Rxn6 (Protein binding domain of SMAR1) along with GST and bead only controls was used for
in-vitro pull down assays for DNA-protein interactions. The resulting DNA fragments were amplified by PCR using GAD65 (C) and GAD67 (D)
specific primers.
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general consensus oligonucleotide were individually
coupled to CNBr beads and Rin 5f cell lysate was passed
through the column. The protein samples were eluted
from the CNBr columns and processed for Western
blotting using SMAR1 specific antibody. Our result
showed that SMAR1 bound with equal propensity to
both GAD65 promoter sequence and the general con-
sensus oligo (Figure 1B, lanes 4 and 5). In-vitro pull
down assays followed by PCR amplification showed that
GST-p53, 350–548 aa (DNA binding domain of SMAR1,
36) and the full-length SMAR1 were able to precipitate
GAD65 promoter (Figure 1C, lanes 2, 3 & 4). The pro-
tein binding domain of SMAR1 i.e. GST-SMAR1 (160–
350 aa), GST bound beads and glutathione beads alone
did not show any amplification (Figure 1C, lanes 5–7)
showing the specificity of the interaction. All these
samples were further analyzed for GAD67 promoter
binding. While we detected GAD67 promoter bound
to GST-p53, neither the full length nor the DNA bind-
ing domain of SMAR1 showed any binding to GAD67
promoter (Figure 1D, lane 2). It is well known that
p53 binds to GAD67 promoter [34]. From the above
mentioned results, it is clear that SMAR1 specifically
binds to the consensus sequence in GAD65 promoter.
GAD65 has a TATA less promoter and various other
factors are known to regulate it. Therefore we analyzed
GAD65 promoter for other transcription factor binding
sites in silico. A careful analysis of the sequence showed
that SMAR1 binds 870 bp upstream of transcriptionstart site. We found a strong p300 consensus element
(~820 bp upstream) and a p53 binding site (~560 bp)
juxtaposed to SMAR1 binding sites. A detailed map of
various binding sites is shown in Additional file 1.
SMAR1 binds to GAD65 promoter and upregulates its
expression
We further verified the binding of SMAR1 to GAD65 pro-
moter using mobility shift assays. A 120 bp probe from
GAD65 promoter which harbors the potential MAR and
SMAR1 consensus binding site was radiolabelled and used
for the assays. EMSA using radiolabelled GAD65 pro-
moter probe showed a SMAR1-DNA complex formation
(Figure 2A, lane 2) and a cold competitor reduced this
complex formation (Figure 2A, lane 3) showing the speci-
ficity of binding. GAD67 and Actin (Figure 2B lanes 1–3
and 4–6 respectively) promoter specific probes did not
show any complex formation with SMAR1 recombinant
protein. Also, competition with cyclin D1 promoter oligo,
greatly reduced the complex formation on GAD65 oligo
and reflected the specificity of the complex formation
(Figure 2C lane 3). Similarly, super-shift assays with
SMAR1 specific antibody on using Rin cell lysate helped
document SMAR1 complex formation on GAD65 pro-
moter oligo (Figure 2D lane 2 and 3). The use of cold
competitor in this experiment significantly reduced the
specific complex formation (Figure 2D, lane 4).
After confirming that SMAR1 binds to GAD65 pro-
moter, we proceeded to check the in vivo effect of
SMAR1 binding on the promoter. It is known that
Figure 2 SMAR1 binds to GAD65 promoter. A. Electro mobility Shift assay (EMSA) was done using GAD65 promoter DNA fragment which is
bound by GST-SMAR1 in EMSA (lane 2) while cold competitor (C.C.; lane 3) reduced the binding showing the specificity of the interaction. B.
Promoter fragments of GAD67 and actin was used as negative controls and did not show any binding with GST-SMAR1 proteins. C. Competitive
EMSA shows SMAR1 interaction with GAD65 promoter (lane 3) is greatly reduced in presence of a competitor of cyclin D1 promoter oligo
compared to no competition lane (lane 1). D. Supershift assay using Rin5f cell lysate without (lane 2) or with SMAR1 antibody (lane 3) showing
shift in the GAD65 promoter band. The upper band in lane 3 represents GAD65-SMAR1-SMAR1 ab complex while lower band shows SMAR1-
GAD65 promoter complex only. E. Luciferase assay showing that SMAR1 and p53 together leads to up-regulation of GAD65 promoter activity.
Coexpression and knock down of SMAR1 and p53 in various combinations was used to look of luciferase activity of GAD65 promoter. F. Rin 5f
cells were treated with FLAG-SMAR1 as well as siRNA of SMAR1 and western blot was carried out to test their effect over SMAR1 expression
(upper panel). Similarly cells were treated with FLAG-p53 as well as siRNA of p53 and western blot using p53 antibody was done to check its
expression levels (lower panel).
Singh et al. BMC Molecular Biology 2012, 13:28 Page 4 of 12
http://www.biomedcentral.com/1471-2199/13/28GAD65 is the predominant form in rat while in mouse
both the forms are expressed. Rat insuloma cell line
Rin 5f cells were co-transfected with a luciferase re-
porter construct driven by GAD65 promoter, and ex-
pression plasmids/siRNAs of SMAR1 and p53. The
results show that GAD65 promoter drives the expres-
sion of reporter gene upon over-expression of SMAR1
or p53 witnessed by an increase of ~ 4 and~ 4.5 folds
respectively (Figure 2E). On the other hand, knock-
down of either of these proteins leads to a decreased
luciferase activity driven by GAD65 promoter. Over-
expression of SMAR1 and p53 together lead to the
highest luciferase counts (~ 6 folds increase) indicating
their additive effect on GAD65 promoter. On the
other hand the knockdown of both lead to negligible
promoter activity. Knock-down of p53 and over ex-
pression of SMAR1 partially rescued (~ 1.5 folds) the
luciferase activity. These results indicate that although
SMAR1 or p53 individually can up-regulate GAD65
promoter activity, their synergistic activity is required
for maximal promoter activity that in turn reflects the
transcriptional activation. On the other hand, eitherone of them is indispensible for activation of GAD65
promoter. It has been reported that phosphorylation of
SMAR1 at serine 370 residue reduces its DNA binding
activity [30; unpublished data]. Transfection of S370A
mutant-SMAR1 led to a reduced GAD65 promoter ac-
tivity compared to the wild-type SMAR1. This was not
overcome by ectopic expression of p53 (Figure 2E,
lanes 8 & 9 respectively). This result clearly indicates
that direct binding of SMAR1 is essential for GAD65
promoter activation and that the effect of SMAR1 is
not through stabilization/activation of p53. In order to
verify our results we performed western blot analysis
to confirm over expression as well as siRNA mediated
knockdown of SMAR1 and p53. Figure 2F shows the
expression levels of SMAR1 (upper panel) as well as
p53 (lower panel) in Rin5f cells.
SMAR1 leads to upregulation of GAD65 expression
Next we verified the expression of GAD65 upon over ex-
pression of SMAR1. RT-PCR results showed that upon
SMAR1 over expression, GAD65 and p53 mRNA levels
are elevated in a dose dependent manner (Figure 3A).
Figure 3 SMAR1 upregulates GAD65 expression. A. RT-PCT analysis of GAD65 and p53 upon dose dependent SMAR1 over-expression. Actin
was used as loading control. B. Densitometric analysis of the RT-PCR showing ~4 fold increase in p53 and ~7 fold increase in GAD65 mRNA levels
upon SMAR1 over-expression. C. SMAR1 was over-expressed in Rin5f cells and samples were processed for western blot analysis 48 hrs post
transfection. Figure shows western blot analysis of these samples using GAD65, phospho serine 15 p53 and SMAR1 expression while actin was
used as loading control. D. SMAR1 and p53 over expression leads to up-regulation (lanes 2 & 3) while their knock-down abolish the basal
expression of GAD65 (lanes 4 & 5). E. DNA binding domain (F5), protein interaction domain (F6) of SMAR1 and full length SMAR1 (FS)
transfections led to increased expression of GAD65.
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transfection of 2 μg of SMAR1, GAD65 mRNA levels
were 7 folds higher compared to the control cells,
while p53 mRNA levels were increased by 3 folds
(Figure 3B). Similarly, western blot analysis of the same
showed increased GAD65 protein levels in a dose
dependent over-expression of SMAR1. Earlier it has
been reported that SMAR1 leads to phosphorylation of
p53 at serine 15 and subsequent stabilization [41-43].
We also observed increased serine 15 phosphorylation
as well as total p53 levels (Figure 3C). Actin was used
as loading control. Also, our results showed that over
expression of either of SMAR1 or p53 lead to elevated
GAD65 protein levels while their knockdown decreased
GAD65 expression (Figure 3D). We then transfected
different truncations of SMAR1 pertaining to DNA
binding (350–548 aa; F5) and protein interacting do-
main (160–350 aa; F6) of SMAR1 along with the full
length SMAR1. Our results showed that full length as
well as DNA binding domain of SMAR1 lead to
increased expression of GAD65 (Figure 3E). Thus, our
results show that DNA binding activity of SMAR1 is
necessary for upregulation of GAD65 expression, while
the protein interacting domain which has been shown
to phosphorylate and activate p53 is not sufficient to
drive p53 dependent expression of GAD65.STZ induced DNA damage leads to upregulation of
GAD65, SMAR1 and p53
It is known that GAD67 and p53 expression increases
upon STZ treatment [34], which prompted us to verify
the effect of STZ on SMAR1. As reported earlier,
SMAR1 is a DNA damage responsive protein and is
upregulated upon DNA damage induced by H2O2, γ-ir-
radiation, Camptothecin and Doxorubicin. Our results
here show that STZ treatment to Rin cells led to ele-
vated mRNA levels of SMAR1, p53 and GAD65 in a
dose dependent manner (Figure 4A). Western blotting
of the same showed that SMAR1, p53 and GAD65 pro-
tein levels were elevated upon 4 mM STZ treatment.
Interestingly Serine 15 as well as ser 46 phosphorylation
of p53 also increases, indicating that prolonged STZ
treatment leads to apoptosis through serine 46 phos-
phorylation of p53 (Figure 4B). FACS analysis of the cells
also showed increased number of apoptotic cells upon
STZ treatment (Figure 4C). Therefore, we examined the
kinetics of SMAR1 and p53 binding to GAD65 promoter
upon STZ treatment. Rin cells were treated with STZ
for indicated time points and processed for ChIP ana-
lysis. Our results show that there is increased binding of
SMAR1 as well as p53 on GAD65 promoter in a time
dependent manner upon STZ treatment (Figure 4D).
Histones on GAD65 promoter were hyper-acetylated in
Figure 4 STZ treatment leads to upregulation of SMAR1, p53 and GAD65 expression. A. RIN cells were treated with STZ in a dose
dependent manner as indicated for 24 hrs followed by RT-PCR analysis of SMAR1, p53 and GAD65 mRNA expression. B. Western blot analysis of
SMAR1, ser46 p53, ser15 p53, total p53 and GAD65 expression upon 4 mM STZ treatment in a time dependent manner. C. Same cells treated
with 4 mM STZ were used for FACS analysis at indicated time points. D. RIN cells were treated with 4 mM of STZ and cells were harvested after
indicated time points. The samples were than processed for ChIP analysis of GAD65 promoter upon STZ treatment for binding of p53, SMAR1,
p300 along with various chromatin activation and repression markers. E & F. ChIP analysis of upstream promoter region of GAD65 (E) and actin
(F) which were used as negative controls did not show any binding by SMAR1 or p53. The ChIP markers used represent activation (p300 & Ac
H3K9) as well as repression (Me3H4K20 & HDAC1) of transcription.
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tion. The increase in recruitment of p300 to GAD65
promoter indicates chromatin activation that is reflected
in increased GAD65 expression. On the other hand
HDAC1 as well as Me3H4K20 showed time dependent
loss of binding to GAD65 promoter (Figure 4E). HDAC1
recruitment causes local deacetylation of the chromatin
thus leading to repressed state. Tri methylation of his-
tone 4 lysine 20 residue is also indicative of the com-
pact/repressed state of chromatin. All these results
indicate that upon STZ treatment, SMAR1 and p53
binds to GAD65 promoter and recruit p300 which then
leads to activation of GAD65 promoter. Upstream pro-
moter region of GAD65 and actin promoter served as
negative controls (Figure 4E, F).
Effect of STZ treatment on mouse β-islets
After verifying that SMAR1 leads to increased expres-
sion of GAD65 upon STZ induced DNA damage, we
wanted to verify our results in-vivo. Mouse β-islets were
isolated using collagen as detailed in materials andmethods section and were cultured for 6 hrs prior to
treatment. The islets were then treated with high
(33 mM) and low (7 mM) dose of glucose, p53 activity
inhibitor Pifithrin-α PFT and STZ (4 mM) for 24 hrs fol-
lowed by confocal as well as RT-PCR analysis. Confocal
results showed that STZ treatment leads to increased ex-
pression of SMAR1, p53 as well as GAD65 (Figure 5A &
B). Phosphorylation of SMAR1 at serine 370 residue is
also increased upon STZ treatment (Figure 5A). This
post-translationally modified form of SMAR1 is known
to have higher affinity for DNA [30]. On the other hand
the islets treated with PFT along with STZ did not show
much change in GAD65 expression indicating that p53
is required for its higher expression.
RT-PCR in the islets showed that treatment with high
glucose or STZ lead to increased expression of SMAR1,
GAD65 and p53, while mdm2 mRNA levels are reduced
(Figure 5C). Actin was used as loading control. On the
other hand, islets treated with both p53 inhibitor PFT and
STZ showed only a marginal increase in GAD65 expres-
sion indicating that although SMAR1 alone can up-
Figure 5 STZ treatment in mouse β-islets leads to upregulation of SMAR1, p53 and GAD65 expression. A & B. β-islets were treated with
STZ and PFT individually as well as in combination followed by fluorescent staining using S370-SMAR1 (phosphor SMAR1 at S370 locus), total
SMAR1, P53 and GAD65 antibodies. DAPI was used as nuclear marker to distinguish between cytoplasm and the nucleus. C. RT-PCR analysis of
SMAR1, p53 and GAD65 upon streptozotocin (STZ), pifithrin-α (PFT) and PFT + STZ treatments. Actin was used as internal loading control. D. The
same RT-PCR data was used for densitometric analysis. The graph indicates the respective expression of GAD65, p53 and SMAR1 expression at
different treatments while the expression in control cells is taken as 1. Thus these values indicate expression comparison of a single molecule
with different treatments and cannot be used to compare expression of two different genes.
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of SMAR1 and p53 is needed for sustained levels of
GAD65 (Figure 5C, lane 3). The densitometric analysis of
RT-PCR shows that upon STZ treatment, p53, SMAR1
and GAD65 mRNA levels increase by ~2.1; ~2.7 & ~3.2
folds respectively (Figure 5D). This increased GAD65 is
secreted in the circulation and is considered as the first in-
jury marker for β-islet injury [37].
Discussion
Transcription factors play an important role in regula-
tion of gene expression through their DNA binding
properties. In order to understand the different functions
of a transcription factor, elucidation of its target genes is
of utmost importance. As discussed earlier, SMAR1 is a
transcription factor and is involved in various cellular
pathways through regulation of target gene expression
like Cyclin D1 [36], CK8 [37] and Bax [46]. In order to
further delineate various promoters bound by SMAR1,
we employed a novel in vitro binding assay using recom-
binant GST-SMAR1 protein. Our protocol involvedin vitro binding of recombinant protein with sonicated
mouse genomic DNA fragments. The high salt buffer
maintains a stringent condition for protein-DNA inter-
action. Subsequent cloning and sequencing of pulled
DNA fragments lead to validation of known SMAR1 tar-
get promoters as well as elucidation of many new pro-
moter fragments, GAD65 being one of them. The
interesting aspect of this interaction was that SMAR1
was specifically binding to only GAD65 and not to the
promoter of other isoform GAD67. Since GAD65 is a
crucial protein in the induction of diabetes, we investi-
gated the mechanism of its regulation by SMAR1. The
major phenotype in type-1 diabetes is apoptosis, result-
ing in a progressive loss of pancreatic beta cells through
autoimmune attack. On the other hand it has been
shown that over-expression of GAD65 transgene in ani-
mal tissues can exacerbate the disease instead of toleriz-
ing the animal though the exact mechanism remains
unclear [4]. Another study using fetal mouse tissue,
showed upregulation of GAD in pancreatic islet cells.
This upregulation was shown to be caused by an
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IDDM. Impairment of mitochondria resulted in an accu-
mulation of glutamate that directly induced the upregu-
lation of GAD in the cells [45]. It is speculated that
GAD expression on pancreatic beta cells may be
involved in the modulation of beta cell specific auto-
immune response and/or modulation of the functional
state of beta cell [47]. Much of the accumulated data
from Type-1 animal models has come from the discov-
ery of a novel diabetogenic compound Streptozotocin
(STZ). The influence of STZ on the modulation of GAD
expression has been shown earlier on GAD67 in MIN
cells and also the INS cells treated with STZ show
increased release of GABA in the culture medium that
indirectly measures the rate of GAD expression [34,48].
Several key transcriptional factors like NFκB and p53
have been shown to regulate the expression of GAD. Al-
though it has been shown that STZ can regulate GAD67
but its effect on GAD65 expression has not been pre-
cisely evaluated [34].
In the present study we for the first time show that
SMAR1 binds to GAD65 promoter but not GAD67.
Using a novel in-vitro pull down assay we derived a con-
sensus DNA binding site for SMAR1. Bioinformatics
analysis of various known SMAR1 binding sequences
revealed that there is significant similarity between DNA
sequences where SMAR1 binds. For example, Cyclin D1
and GAD65 share the identical hexamer sequence in
their promoter where SMAR1 binds. CNBr pull down
assay followed by western blotting (South-western blot-
ting) confirmed that SMAR1 binds to the consensus as
well as GAD65 promoter. Binding of SMAR1 to GAD65
promoter was further verified using EMSA. Our results
suggest that SMAR1 and p53 binds to GAD65 promoter
and synergistically regulate its expression. Transient
transfections of SMAR1 or p53 followed by RT-PCR as
well as luciferase assays showed that SMAR1 as well as
p53 individually can up-regulate GAD65 expression. On
the other hand whenever transfected together, the
GAD65 expression increased many fold, indicating that
both SMAR1 and p53 act cumulatively leading to an
increased expression of GAD65. Our results indicate
that DNA binding domain binds to GAD65 promoter
while protein interacting domain might recruit various
other transcription factors leading to upregulation of
GAD65 promoter.
In our model also we have investigated the possible
role of STZ in modulation of GAD65 expression
through co-ordinated interaction of p53 and SMAR1.
We first examined the effect of STZ on the expression
of GAD65, p53 and SMAR1 in rat beta cell line,
RINm5f. We found that STZ significantly enhanced the
expression of p53, SMAR1 and GAD65 molecules both
at mRNA and protein level. This increased expressionwas observed in a time and dose dependent manner
STZ treatment also led to increased phosphorylation of
p53 at serine 15 as well as serine 46. Serine 15 phos-
phorylation of p53 indicates the activation of p53 while
phosphorylation at serine 46 phosphorylation generally
leads to apoptosis. FACS analysis also showed increased
amount of apoptosis 36 h post STZ treatment. Collect-
ively, our results showed that STZ treatment leads to
upregulation of GAD65 expression ultimately leading to
apoptosis. We further wanted to see the kinetics of bind-
ing of SMAR1 and p53 to GAD65 promoter upon STZ
treatment. ChIP analysis showed that there is a time
dependent increase in association of SMAR1 and p53 on
GAD65 promoter. Markers for chromatin activation
AcH3K9 also showed increased amplification. The in-
crease in recruitment of p300 to GAD65 promoter indi-
cates chromatin activation that is reflected in increased
GAD65 expression. On the other hand HDAC1 as well
as Me3H4K20 showed time dependent loss of binding to
GAD65 promoter. All these results indicate that upon
STZ treatment, SMAR1 and p53 binds to GAD65 pro-
moter and recruits p300 which leads to activation of
GAD65 promoter. We further verified our results using
mouse β-islets. Our results showed that STZ mediated
upregulation of GAD65 expression is dependent on con-
flated action of p53 and SMAR1.
Interestingly, the analysis of promoter sequences of
GAD65 across species from Human, mouse, rat and
found that SMAR1 bound sequence is rather conserved
amongst these species. Further alignment of mouse
GAD65 promoter sequences with guinea pig, monkey,
Bos Taraus and chimpanzee genomes showed that there
is a great degree of conservation amongst all these
species. The detailed alignment study is described in
Additional file 2.
Thus our study for the first time shows the involve-
ment of a MAR binding protein SMAR1 in regulation of
GAD65 expression. p53 is already known to bind to and
regulate expression of GAD67 isoform of GAD. In the
present study we show that p53 also regulates expression
of GAD65. Upon STZ treatment SMAR1 and p53 leads
to upregulation of GAD65 expression which may be
secreted in the blood. This circulating GAD65 is consid-
ered as an early marker for β-cell injury [37]. Taken to-
gether, our results show that GAD65 acts as one of the
major injury marker as well as immuno-modulator. Thus
regulation of GAD65 expression in β-islets by SMAR1
and p53 presents another facet of their involvement in
DNA damage response.
Conclusions
The present study delineates yet another facet of regula-
tion of GAD65 expression by two tumor suppressor pro-
teins SMAR1 and p53 synergistically. The study
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library of DNA fragments bound to a protein in-vitro.
By employing various techniques like ChIP, south western
assays to study kinetics of DNA-protein interactions, we
show that SMAR1 and p53 binds to GAD65 promoter in
close vicinity to each other and upregulate GAD65 expres-
sion in a time and dose dependent manner upon STZ
treatment. Induction of stress to β-islets by streptozotocin
causing activates p53 and SMAR1 which inturn bind to
GAD65 promoter and upregulating its expression. This
increased production of GAD65 protein may be secreted
in blood and detected as injury/stress marker to β-islets
during onset of diabetes.
Methods
In-vitro DNA pull down assay and sequence alignment
This assay is designed to use recombinant proteins to
elucidate DNA fragments associated with the protein.
GST-SMAR1 recombinant protein was purified as per
the previously described protocol [49]. The purity of re-
combinant protein was validated using 8% SDS-PAGE
followed by silver stain. Mouse genomic DNA was
sheared using Sonicator to obtain small fragments of ap-
proximately 500 bp. The purity and length of DNA was
verified by running on 1.2% agarose gel. Just before the
pull down reaction, the frozen recombinant protein was
ultracentrifuged at 1, 00,000 rpm at 4°C to remove all
the debris and unwanted protein aggregates. The DNA
fragments were then incubated with glutathione bead
bound GST-SMAR1 recombinant protein in DPD buffer
(20 mM HEPES pH7.9, 1 mM EDTA, 30 mM KCl,
100 mM NaCl, 1 mM DTT, 25% Glycerol and 0.2%
Tween-20) for 1 hrs at room temperature. The beads
were than washed thrice with same buffer but increasing
concentration of NaCl (100, 200, 300 mM NaCl) and
bound DNA fragments were separated using phenol
chloroform extraction. The fragments were than cloned
into pGEMT easy vector and were subsequently
sequenced using T7 specific primer. Glutathione beads
as well as bead bound GST only were the controls used
to rule out the non specific DNA binding of the recom-
binant protein. The resulting sequences were than
aligned using MEME software and a 50mer consensus
was derived.
Cell culture and treatments
For in-vitro assays, RINm5F cell line was provided by
NCCS cell repository. RINm5F cells were cultured in
RPMI medium with 10% FCS in CO2 incubator. 1 μg of
SMAR1, p53 or pTU puro SMAR1 (SiRNA) DNA was
used for transfection per well using lipofectamine. P53
siRNA was procured from Santa Cruz and was used as
per manufacturer’s instructions. For in-vivo experiments
4–6 weeks old C57b6, SMAR1 transgenic and p53 nullmice were kindly provided by NCCS animal house facil-
ity. The animal studies were conducted in accordance
with Principles of Laboratory Animal Care. STZ was
reconstituted in chilled phosphate citrate buffer, pH 4.5
and immediately used for treatments.
Immunoblotting and antibodies
Cells were scraped in 1XPBS and collected at indicated
time points. Cells were then lysed using TNN buffer and
protein concentration estimated using Bradford reagent
(Bio-Rad). Equal amounts of proteins were taken for im-
munoblotting. Following sodium dodecyl sulphate
(SDS)–polyacrylamide gel electrophoresis, the resolved
proteins were electro blotted onto PVDF membrane
(Amersham). The membrane was blocked overnight in
Tris-buffered saline containing 0.1% Tween-20 (TBST)
and 10% bovine serum albumin (BSA). The membrane
was then probed with primary antibody in TBST for 2 h,
followed by three 10-min TBST washes at room
temperature. Incubation with the secondary antibody
was done for 1 h, and three 10-min TBST washes were
given prior to detection. Proteins were detected using
enhanced chemiluminescence substrate (Amersham).
The primary antibodies used were SMAR1 and S370
SMAR1 (Rabbit Polyclonal antibody raised in the lab;
49), p53 DO1 and actin (mouse monoclonal antibodies,
Santa Cruz), ser15 p53 (#9284, Rabbit polyclonal; cell
signaling), ser 46 p53(#2501, Rabbit Polyclonal; cell sig-
naling), Ac 373/382 p53 (#2525, Rabbit Polyclonal; cell
signaling) and GAD65 (mouse monoclonal antibody,
#ab85866, Abcam). The secondary antibodies were don-
key α-goat, donkey α-rabbit, donkey α-mouse (Bio-Rad).
Purification of GST fusion protein
GST-SMAR1 as well as GST (160–350) and GST (350–
548) truncation clones of SMAR1 are different trunca-
tions of total SMAR1 protein having DNA binding and
protein interaction domains respectively [36,41]. All
clones were grown in Luria-Bertani medium with
ampicillin and induced with 1 mM isopropyl-D-
thiogalactopyranoside (IPTG). Cells were resuspended in
lysis buffer containing phosphate-buffered saline (PBS),
Triton X-100, and protease inhibitors (Roche). After son-
ication and centrifugation, supernatant was incubated
with glutathione Sepharose beads (Amersham) for 1 h at
4°C with gentle agitation. After three washes, with lysis
buffer and PBS, the proteins were eluted at room
temperature with 100 mM reduced glutathione buffer.
Electrophoretic mobility shift assay (EMSA)
For EMSA, oligonucleotide labelling was done by a
Klenow reaction using [α32P] dCTP in a 20 μl reac-
tion containing 1 mM dATG mix, Klenow buffer, and
0.5U of Klenow DNA polymerase (Invitrogen). Probe
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(Amersham Biosciences). Binding reactions were per-
formed in a 10 μl total volume containing 10 mM
HEPES (pH 7.9), 1 mM dithiothreitol, 50 mM KCl,
2.5 mM MgCl2, 10% glycerol, 0.5 to 1 μg double-
stranded poly (dI-dC), 10 μg BSA and 1 μg of recom-
binant protein. Samples were incubated for 5 min at
room temperature prior to addition of radiolabeled
probe. The samples were then incubated for 15 min
at room temperature, and the products of binding
reactions were resolved using 8% native polyacryl-
amide gel electrophoresis. The gels were dried under
vacuum and processed for autoradiography.
CNBr assay/Immunoaffinity purification
CNBr assay was done using previously described proto-
col by Nagore et al. [50]. GAD65 promoter and control
DNA fragments were amplified by PCR followed be gel
elution for purity. The fragments were than coupled to
CNBr-activated sepharose beads (Stratagene) using
coupling buffer (0.1 M NaHCO3, 0.5 M NaCl, pH 8.3).
The cell lysate was then passed at a slow rate through
the column after washes with equilibration buffer. Pro-
teins were eluted using increasing concentrations of
NaCl, pH 8.0 in 0.1 M Tris–glycine buffer pH 2.5. All
elutes were pooled and concentrated followed by West-
ern blot using SMAR1 antibody.
Luciferase reporter assays
24 hours after transfection, the culture medium was
removed, cells were washed with phosphate buffered sa-
line (PBS), resuspended in 100 μl of cell lysis buffer.
After freeze-thawing twice, lysed cells were spun at
9500 rpm for 15 min. Equal amount of protein was used
for the assays. Luciferase activity was measured with
Luclite substrate (Perkin Elmer, USA) and assay reac-
tions read using Top-Count luminometer (Packard Life
sciences, USA). Graphs were plotted from data obtained
as a mean of 3 independent experiments along with
computed standard deviations as error bars. The se-
quence of GAD65 promoter fragment used for luciferase
assay is given in supplementary Figure 1.Table 1 Primer sequences used for ChIP PCR analysis
Primer Name Sequ
GAD 65 promoter (Fwd) 5’CT
GAD 65 promoter (Rev) 5’TG
GAD 67 promoter (Fwd) 5’CA
GAD 67 promoter (Rev) 5’AG
Actin Promoter (Fwd) 5’GC
Actin Promoter (Rev) 5’GC
Consensus sequences (double stranded) 5’TAChIP analysis
Assays were performed using Chromatin Immunopreci-
pitation (ChIP) assay kit (Upstate Biotechnology) follow-
ing manufacturer’s instructions. 1x106 cells were plated
per 30 mm dish and treated with 3 mM STZ or left un-
treated. After treatment, DNA-protein interactions were
fixed by adding formaldehyde directly to the media to a
final concentration of 1%, incubated at 37°C for 10 min.
Cells were washed with 1X PBS, pelletted and lysed in
SDS-lysis buffer by sonication. The samples were then
centrifuged at 15,000 rpm in order to clear the debris
and chromatin extracts were incubated with 2 μg of the
indicated antibody isotype control antibody and rotated
at 4°C for 8–12 h. The antibody-chromatin complex was
precipitated by adding protein A-sepharose bead, incu-
bated for 4 h by rotating at 4°C and centrifuged at
3,000 rpm for 5 min. ChIP assays were carried out using
SMAR1, HDAC1, acetyl Histone 3 Lysine-9 (H3K9),
Histone 4 Lysine 16 (H4K16) and p53 antibodies (Cell
Signaling). Input DNA, Rabbit IgG (r-IgG), and Mouse
IgG (m-IgG) pulled DNA served as controls for all the
experiments. Immunoprecipitated DNA was then sub-
jected to 30 cycles of semi-quantitative PCR using the
primers mentioned in Table 1.
Cell cycle analysis by FACS
DNA content of cells was measured to check apoptosis.
1x 106 RINm5F cells were seeded in a 6-well plate
24 hours before the day of experiment. RINm5F cells
were treated with different concentrations of STZ 1, 2.5,
5 and 10 mM for 24 hours. The cells were fixed with cold
70% ethanol overnight and then treated with 10 μg/ml
RNase at 37°C for 30 min. DNA content was measured
by staining cells with propidium iodide (50 μg/ml) for
15 min. at RT. Apoptotic cells show low DNA stain abil-
ity resulting in a distinct, quantifiable region at sub-GO/
G1 peak and analyzed by flow cytometry at 620 nm.
β-islet isolation
Pancreas was dissected out from the mice and minced
with scissor. Then 1–2 washings were given with plain
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flask islet dissociation medium containing collagenase
(Roche) and soybean trypsin inhibitor (Sigma-Aldrich)
was added on the tissue and the mixture was stirred for
20 minutes. An ice cold RPMI with 10% FCS was added
to stop the reaction. Mixture was centrifuged at low
speed and the pellet was suspended in plain RPMI. The
suspension was vortexed to detach acinar cells from is-
lets and centrifuged again. Now the pellet was sus-
pended in RPMI and floating islets were carefully
removed by hand picking under microscope and pro-
ceeded for further treatments. The purity of the islets
was confirmed using insulin staining.
RT-PCR
Total RNA from RINm5F and islets was isolated by Tri-
reagent (Sigma-Aldrich) according to manufacturer’s
protocol. In brief, RINm5F cells or islets were lysed in
Tri reagent by pipeting several times and mixed with
chloroform and centrifuged at 12,000 g for 15 minutes.
The aqueous phase was removed and RNA was precipi-
tated in isopropanol. The RNA was pelletted at 10,000 g
for 10 minutes, washed with ethanol and centrifuged.
The pellet was air dried and suspended in DEPC water.
cDNA was synthesized using 5 μg RNA as template in
presence of MMLV-RT, MMLV-RT buffer, 10 mM
dNTPs, DTT and RNAse OUT (All reagents were pur-
chased independently from Invitrogen).
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Additional file 1: Regulation of GAD65 expression by SMAR1 and
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